CN105878322A - Sunflower head extract prepared by crystallization enzymolysis method and preparation method of sunflower head extract - Google Patents
Sunflower head extract prepared by crystallization enzymolysis method and preparation method of sunflower head extract Download PDFInfo
- Publication number
- CN105878322A CN105878322A CN201610294538.7A CN201610294538A CN105878322A CN 105878322 A CN105878322 A CN 105878322A CN 201610294538 A CN201610294538 A CN 201610294538A CN 105878322 A CN105878322 A CN 105878322A
- Authority
- CN
- China
- Prior art keywords
- receptaculum helianthi
- freezing
- extract
- receptaculum
- uric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 13
- 238000002425 crystallisation Methods 0.000 title claims abstract description 11
- 230000008025 crystallization Effects 0.000 title claims abstract 3
- 241000208818 Helianthus Species 0.000 title abstract description 17
- 235000003222 Helianthus annuus Nutrition 0.000 title abstract description 17
- 201000005569 Gout Diseases 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 7
- 239000008103 glucose Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 230000008014 freezing Effects 0.000 claims description 30
- 238000007710 freezing Methods 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 26
- 238000000605 extraction Methods 0.000 claims description 24
- 239000012141 concentrate Substances 0.000 claims description 15
- 229930003944 flavone Natural products 0.000 claims description 14
- 235000011949 flavones Nutrition 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 235000008504 concentrate Nutrition 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108091005804 Peptidases Proteins 0.000 claims description 11
- 239000004365 Protease Substances 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 150000002213 flavones Chemical class 0.000 claims description 10
- 229930013930 alkaloid Natural products 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 238000000108 ultra-filtration Methods 0.000 claims description 8
- 102000057297 Pepsin A Human genes 0.000 claims description 7
- 108090000284 Pepsin A Proteins 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 229940111202 pepsin Drugs 0.000 claims description 7
- 102000004142 Trypsin Human genes 0.000 claims description 6
- 108090000631 Trypsin Proteins 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 235000012489 doughnuts Nutrition 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 229930182830 galactose Natural products 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- -1 Micropill Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 35
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 32
- 229940116269 uric acid Drugs 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 20
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 208000002193 Pain Diseases 0.000 abstract description 9
- 230000036407 pain Effects 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 5
- 230000008961 swelling Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 4
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 230000008821 health effect Effects 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 108010093894 Xanthine oxidase Proteins 0.000 description 5
- 102100033220 Xanthine oxidase Human genes 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004144 purine metabolism Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000006825 purine synthesis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101800000628 PDH precursor-related peptide Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010041290 Soft tissue inflammation Diseases 0.000 description 1
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- FPVGTPBMTFTMRT-NSKUCRDLSA-L fast yellow Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-NSKUCRDLSA-L 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides sunflower head extract prepared by a crystallization enzymolysis method and a preparation method of the sunflower head extract. A sunflower head is a pure natural traditional Chinese medicine or a material both used as medicine and food; the sunflower head is scientifically extracted to prepare a functional health product both used as medicine and food, which has the effects of resisting gout, treating hyperuricemia, improving the immunity, lowering blood glucose and blood lipid, protecting kidney and liver, eliminating swelling, resisting inflammation and relieving pain and has the effects of dissolving uric acid calculus, lowering serum uric acid concentration, eliminating swelling and resisting inflammation, adjusting purine and uric acid metabolism, balancing in-vivo acid-base equilibrium and balancing in-vivo hormones; the product is safe, has no side effect, has remarkable health effect and can be eaten for a long period, so that a market development prospect is very good.
Description
Technical field
The invention belongs to the field of Chinese medicines, particularly relate to a kind of suspended crystallization method and Receptaculum Helianthi extract prepared by enzymatic isolation method
And preparation method thereof, and for preparing the purposes of the medicine of prevention and treatment gout.
Background technology
Gout is a kind of metabolic disease caused by purine metabolic disturbance, and serum Uric Acid Concentration raises, and sodium urate crystals is deposited on
Lower limb bone joint, tremulous pulse, vertebrae gap tissue and cause, show as joint red, swollen, hot, bitterly, joint motion is unfavorable, seriously
Person is joint deformity and dysfunction, and has the feature of recurrent exerbation.The existence of gout can also result in coronary heart disease, diabetes,
The deterioration of the diseases such as hypertension.In terms for the treatment of, western modern medicine treatment gout, the method that there is no radical cure, colchicine, nonsteroidal
Though the medicine such as anti-inflammatory agent, allopurinol can mitigation symptoms, reduce blood uric acid, but its effect is more single, very difficult fundamentally treats
Gout, and the injury that health is caused by this type of Western medicine of long-term taking is many more than therapeutic effect.And Chinese medicine gout, side effect
Few, easily it is accepted by patients, thus reaches long-term prescription, the purpose of final radical curing of disease.But, traditional Chinese medicine gout
Method there is problems: the understanding of gout pathogenesis is also lacked common recognition, the more difficult unification of differentiation of symptoms and signs for classification of syndrome；Clinical report is more,
For want of compare, have impact on the reliability of therapeutic outcome；Plus-minus person is many for decoction, and fixed dosage form is few, and mechanism of drug action lacks dynamic
The checking of thing test.Up to now, not yet there is well treatment gout medicine.
Receptaculum Helianthi is except sunflower plate after Semen Helianthi, and theory of Chinese medical science is thought: floral disc of sunflower, and the property of medicine is sweet, cold, returns Liver Channel,
Function heat clearing away suppressing the hyperactive liver, analgesic hemostatic；Cure mainly hypertension, headache and dizzy, tinnitus, dysmenorrhea, metrorrhagia, skin ulcer rash." Hebei medium-height grass
Medicine " say: " Receptaculum Helianthi heat clearing and damp drying, eliminating stagnation of having a respite.Controlling headache, dizziness, acute toothache, conjunctival congestion nebula, suffers from abdominal pain, is used for outward in throat
Cellulitis ", there is the effect of obvious antiinflammatory, diuresis, blood pressure lowering.
Tradition apply in, it is common that will except after Semen Helianthi Receptaculum Helianthi as animal feeding-stuff pasture or as burning material take
Warm up and cook, do not given play to its bigger economic benefit and medical function, caused the wasting of resources.Along with Receptaculum Helianthi is researched and developed by
Gradually deeply, some documents extracted about Receptaculum Helianthi active component are occurred in that.
Hu Wenbin etc. (" sunflower disc is treated classical prosopalgic preliminary efficacy and is observed ", Anhui medicine, 2013,
Volume 17, the 5th phase, the 828-830 page) inquire into the sunflower disc clinical efficacy to 71 example affected nerves of patients with trigeminal neuralgias, result table
Bright, sunflower disc group and Carbamazepine Tablets group treat prosopalgic total effective rate no significant difference (P > 0.05), Karma
Xiping sheet group is treated prosopalgic obvious effective rate and is significantly higher than sunflower disc group (P < 0.05), but sunflower disc group treats trident
Neuralgic untoward reaction is significantly lower than Carbamazepine Tablets group (P < 0.05).
Chinese patent application CN201210466655.9 utilizes the garbage Flos Helianthi produced in Helianthi recovery process
Dish, the method being carried out enzymolysis by pulverizing, hot-water soak and pectase is obtained Helianthi polysaccharide, and discloses described polysaccharide
There is regulation immunologic function, strengthen the effect of immunological effect.
Chinese patent application CN201510055248.2 provides the sunflower that a kind of extraction ratio is high, energy consumption is low, easy and simple to handle
The extracting method of dish total flavones, is with floral disc of sunflower in florescence for extracting raw material, utilizes SCF-CO 2 method to carry out always
The extraction of flavone separates.With it, the extraction ratio of total flavones can reach 1.93%, but described document does not disclose sunflower
The pharmacologically active of dish total flavones and clinical practice.
China is the plantation big country of Helianthi, the aboundresources of Receptaculum Helianthi.For reduce the wasting of resources, and obtain safely, have
The Receptaculum Helianthi active component of effect, needs the extraction of Receptaculum Helianthi active component is done more in-depth study.
Summary of the invention
In order to overcome wasting of resources present situation in the art, develop Receptaculum Helianthi activity safer, effective
Point, the invention provides a kind of Receptaculum Helianthi extract, it has reduction blood uric acid rich in total flavones, small-molecular peptides and alkaloid,
Eliminating the pain that gout produces, dissolve tophus, effect of anti-inflammation detumescence, prevention and treatment to gout have significantly effect
Really, and toxic and side effects is less, can long-term taking.Meanwhile, be used for preparing the method for Receptaculum Helianthi extract of the present invention easy and simple to handle,
Extraction efficiency is high, production cost is low, is suitable for industrialized great production.
The present invention is achieved by the following technical solutions.
On the one hand, the invention provides a kind of Receptaculum Helianthi extract, comprise total flavones 10-20%, small-molecular peptides 1-3% and life
Alkaloids 10-30%.Preferably, Receptaculum Helianthi extract comprises total flavones 16-20%, small-molecular peptides 2.4-3% and alkaloid 18-30%.
In the Receptaculum Helianthi extract of the present invention, total flavones, small-molecular peptides and alkaloid are effective active composition.Its
In, Receptaculum Helianthi alkaloid can form sunflower alkalinuria acid complex with specific binding uric acid, treats gout；Can suppress fast
Purine synthesis and purine metabolism, reduce internal uric acid content and eliminate uric acid；Suppress the chemotactic of inflammatory cell simultaneously and reduce inflammation
The factor discharges, and the gouty arthritis for acute attack has unique anti-inflammation detumescence effectiveness.Flavone in Receptaculum Helianthi is a kind of
The strongest antioxidant, can the effective oxygen-derived free radicals in purged body, stop the oxidation of nucleic acid, play the effect reducing purine content；
Blood glucose and triglyceride can be reduced, reduce capillary fragility, increase permeability and can alleviate kidney cell pressure, through more
Many uric acid.Kidney protein tubule, beneficially renal metabolism uric acid can be stablized simultaneously.Flavone can also suppress oozing of inflammatory enzyme
Go out, in order to pain relieving.Small-molecular peptides is the material that special for the protein utilization of macromole enzyme resolves into little molecule, by 2 to 10
Amino acid residue molecular forms, and small-molecular peptides directly can absorb through intestinal blood capillary, transports whole body onset, can control
The PRPP amide transferase of purine synthesis, thus suppress the synthesis suppression purine metabolism of purine.Small-molecular peptides can disturb yellow fast
The purine such as purine oxidase are converted into the enzyme of uric acid, thus uric acid content in control volume.Especially for heritability patient with gout, by
In gene delection, lacking the enzyme of purine metabolism, cause uric acid to accumulate, small-molecular peptides can play the effect of certain disappearance enzyme.
The Receptaculum Helianthi extract of the present invention is to use the extraction of smashing extractor Smashing extraction method, suspended crystallization method freezing
The techniques such as concentration, enzymolysis, ultrafiltration, freezing concentrate, is dried are made.Specifically, the Receptaculum Helianthi extract of the present invention is by wrapping
The method including following steps prepares: weighs fresh or freezing and removes the Receptaculum Helianthi of seed, is ground into 80-150 mesh fine powder, adds 5-10
The 15-30% ethanol solution of quality times, is placed in flash extracter and carries out broken extraction, and extraction time is 100-300s, extracts electricity
Pressure is 100-200V, then utilizes suspended crystallization method freezing to concentrate, and adds answering of 0.003-0.005 mass times in concentrated solution
Hop protein enzyme enzymolysis 3-5h, and use doughnut membrane ultrafiltration, filtrate freezing and crystallizing concentrates, and adds appropriate excipient, is spray-dried
Obtain.
Preferably, being 18-20% for extracting the ethanol solution concentration of Receptaculum Helianthi fine powder, freezing temperature is-28
DEG C--40 DEG C.Described compound protease is that pepsin and trypsin are in mass ratio for 1:(1.5-3.0) mixing that mixes
Thing.Described excipient is selected from such as glucose, galactose and/or microcrystalline Cellulose.
Therefore, present invention also offers the preparation method of Receptaculum Helianthi extract, said method comprising the steps of: weigh new
The Receptaculum Helianthi of seed is removed in fresh or freezing, is ground into 80-150 mesh fine powder, adds the 15-30% ethanol solution of 5-10 mass times, is placed in flash
Carrying out broken extraction in extractor, extraction time is 100-300s, and extraction voltage is 100-200V, then utilizes suspended crystallization method
Freezing concentrates, and adds the compound protease enzymolysis 3-5h of 0.003-0.005 mass times, and use hollow-fibre membrane in concentrated solution
Ultrafiltration, filtrate freezing and crystallizing concentrates, adds appropriate excipient, be spray-dried and get final product.
Preferably, in the preparation process in accordance with the present invention, the ethanol solution concentration being used for extracting Receptaculum Helianthi fine powder is 18-
20%, freezing temperature is-28 DEG C--40 DEG C.Described compound protease be pepsin and trypsin in mass ratio
For 1:(1.5-3.0) mixture that mixes.Described excipient is selected from such as glucose, galactose and/or microcrystalline Cellulose.
The Receptaculum Helianthi extract of the present invention can be widely used in medicine and/or health product as active component.Therefore,
Further, the invention provides a kind of pharmaceutical composition, its comprise the present invention Receptaculum Helianthi extract and optional pharmaceutically
Acceptable carrier.Described pharmaceutical composition can be tablet, capsule, drop pill, granule, powder, micropill, solution
Agent, syrup, Emulsion or injection.Such as, for oral formulations, usage and dosage is oral 1-2 times/day, 10-20g/time.Suitable
Answering disease is the prevention and treatment of diseases such as gout, purine metabolic disturbance, blood uric acid height.
The Receptaculum Helianthi extract of the present invention can play its curative effect, to animal acute gouty arthritis by many-side effect
Model has antiinflammatory action, and the pain of chemistry or thermostimulation is had analgesic activity, it is possible to decrease the normal and blood of hyperuricemia animal
Uric acid, to anxious, the subacute inflammation of animal early, the later stage all have antiinflammatory action.The mechanism of its treatment is to be regulated by small-molecular peptides
Internal purine and uric acid metabolism approach, block the metabolic enzyme of uric acid, and flavone compound has easing pain and diminishing inflammation simultaneously, increases kidney little
The effect of pipe metabolism uric acid, Receptaculum Helianthi alkaloid can neutralize uric acid, eliminates uric acid, plays the internal uric acid effect of reduction.Pass through
Oral, uric acid patient in 2 hours 95% patient can reach uric acid resisting effect, take the present invention continuously 1 month, 75% patient's uric acid
Level recovers normal, has no side effect.
Therefore, present invention also offers described Receptaculum Helianthi extract or the pharmaceutical composition comprising this Receptaculum Helianthi extract
Purposes in the medicine of preparation prevention and treatment gout.
The present invention compared with prior art, has the active effect that
Receptaculum Helianthi is the material of natural Chinese medicines or integration of edible and medicinal herbs, has prevention or treatment gout, metabolic arthritis after science is extracted
Mass formed by blood stasis, and the function of functions of detumescence, relieving inflammation pain relieving, and medicine or health product can be further prepared into；
The product safety of the present invention, have no side effect, there is remarkable efficacy, can long-term taking, there is the good prospect of marketing；
The preparation method of Receptaculum Helianthi extract of the present invention is easy and simple to handle, extraction efficiency is high, production cost is low, is suitable for the big life of industrialization
Produce.
Detailed description of the invention:
For making the present invention easier to understand, below in conjunction with specific embodiment, the present invention is expanded on further.These embodiments are only used
In the explanation present invention rather than restriction the scope of the present invention.
Embodiment 1:
The preparation method of Receptaculum Helianthi extract: weigh fresh or freezing and remove seed Receptaculum Helianthi 10kg, Receptaculum Helianthi is ground into 80 mesh thin
Powder, adds 20% ethanol solution of 5 mass times, is placed in flash smashing extractor (Heze Jie Pu Instrument Ltd.) broken extraction,
Extraction time 100s, extracts voltage 150V, and then profit suspended crystallization method freezing concentrates, and freezing temperature is-28 DEG C,
Concentrated solution adds compound protease (pepsin and trypsin mix with mass ratio 1:2) the enzymolysis solution of 0.004 mass times
3h, and use doughnut membrane ultrafiltration, filtrate freezing and crystallizing concentrates, and adds glucose 0.5kg, is spray-dried, subpackage, packaging.
Embodiment 2:
The preparation method of Receptaculum Helianthi extract: weigh fresh or freezing and remove seed Receptaculum Helianthi 20kg, Receptaculum Helianthi is ground into 100 mesh
Fine powder, adds 20% ethanol solution of 8 mass times, is placed in the broken extraction of flash smashing extractor (Heze Jie Pu Instrument Ltd.),
Extraction time 200s, extracts voltage 100V, then utilizes suspended crystallization method freezing to concentrate, and freezing temperature is-40
DEG C, concentrated solution adds compound protease (pepsin and trypsin mix) the enzyme enzyme of 0.003 mass times with mass ratio 1:1.5
Solving, enzymolysis 4h, and use doughnut membrane ultrafiltration, filtrate freezing and crystallizing concentrates, and adds galactose 1kg, is spray-dried, subpackage, bag
Dress.
Embodiment 3
The preparation method of Receptaculum Helianthi extract: weigh fresh or freezing and remove seed Receptaculum Helianthi 30kg, Receptaculum Helianthi is ground into 150 mesh
Fine powder, adds 20% ethanol solution of 10 mass times, is placed in that flash smashing extractor (Heze Jie Pu Instrument Ltd.) is broken to be carried
Taking, extraction time 300s, extract voltage 200V, then profit suspended crystallization method freezing concentrates, and freezing temperature is-30
DEG C, concentrated solution adds compound protease (pepsin and the trypsin mix) enzyme of 0.0048 mass times with mass ratio 1:2.8
Xie Xie, enzymolysis 5h, and use doughnut membrane ultrafiltration, filtrate freezing and crystallizing concentrates, and adds microcrystalline Cellulose 0.5kg, spray dried
Dry, subpackage, packaging.
Embodiment 4
The preparation of tablet: weigh the Receptaculum Helianthi extract 100kg of embodiment 1, adds starch 25kg, microcrystalline Cellulose 10kg and wheat
Bud dextrin 6kg, mix homogeneously, with 40% ethanol solution soft material, cross 25 mesh sieves and pelletize, be dried, cross 20 mesh sieve granulate, add suitable
Amount magnesium stearate, mix homogeneously, tabletting, to obtain final product.
Embodiment 5
The preparation of capsule: weigh the Receptaculum Helianthi extract 150kg of embodiment 2, adds microcrystalline Cellulose 30kg and lactose 12kg,
Mix homogeneously, with 2.0% hydroxypropyl methylcellulose solution soft material, crosses 40 mesh sieves and pelletizes, be dried, cross 30 mesh sieve granulate, add suitable
Amount silica sol, mix homogeneously, fill to capsule shells, to obtain final product.
Embodiment 6
The preparation of thin membrane coated tablet: weigh the Receptaculum Helianthi extract 100kg of embodiment 1, adds starch 25kg, microcrystalline Cellulose
12kg and carboxymethyl starch sodium 8kg, mix homogeneously, with 30% ethanol solution soft material, cross 20 mesh sieves and pelletize, be dried, cross 20 mesh sieves
Granulate, adds appropriate magnesium stearate, mix homogeneously, tabletting, obtains label；Hydroxypropyl methyl cellulose 2.5kg is dissolved in suitable
In amount ethanol solution, and to label spray coating, it is dried, obtains thin membrane coated tablet.
Test example 1: pharmacological is tested
One, test material
1. animal: Kunming mouse, body weight (20g ± 2g), Jilin University's clinic Animal Research Center provide.
2. it is administered sample: blank group (distilled water), of the present invention group (Receptaculum Helianthi that embodiment 1,2,3 prepares carries
Take thing).
Two, test method
1. analgesic experiment: take male mice 40, is randomly divided into blank group, of the present invention group of (embodiment 1, embodiment 2, reality
Execute example).By 100mg kg-1Being administered, 1 time one day, blank group gave equivalent distilled water.Successive administration 5 days, is administered in last
After 1 hour, often organize and take 10 mouse peritoneals and inject 0.7% acetic acid 0.1ml g-1, record writhing time in each group of mice 20min
Number.The results are shown in Table 1.
The impact of table 1. Dichlorodiphenyl Acetate induced mice writhing response
Compare with blank group, * P < 0.05, * * P < 0.01
2. mice foot swelling experiment: take male mice 40, is randomly divided into blank group, of the present invention group of (embodiment 1, enforcement
Example 2, embodiment).Being administered by 100mg kg-1,1 time one day, blank group gave equivalent distilled water.Successive administration 5 days, in
After last is administered 1 hour, every Mus left back toe subcutaneous injection 5%MSU0.08ml, after 5h, cervical dislocation puts to death mice, along naked joint
Cut left and right metapedes at 0.5cm, weigh, using the difference of left and right metapedes quality as inflammation swelling.The results are shown in Table 2.
The table 2 impact on MSU induced mice foot swelling
3. Mouse Blood uric acid (UA), xanthine oxidase (XOD) and blood urea nitrogen (BUN): take male mice 100, be randomly divided into
Normal group, model group, of the present invention group (embodiment 1, embodiment 2, embodiment 3), often group 20.In addition to normal group, often group all with
Yeast 30g kg-1 gavage, continuous one week.Started of the present invention group of gavage from the 3rd day, be administered by 100mg kg-1, successive administration
5d.Mice is extractd eyeball method and takes blood, separates serum, measures UA, XOD and BUN value at wavelength 690nm, 530nm and 640nm.Knot
Fruit is shown in Table 3.
Table 3. causes the impact of hyperuricemia mice serum UA, XOD and BUN to yeast extract
* P < 0.05, * * P < 0.01 is compared with normal group;* P < 0.05, * * P < 0.01 n=20 is compared with model group
Three, result of the test
Gout is that too much or renal excretion uric acid reduces for internal disorders of purine metabolism, uric acid, causes urate in tissue deposition
Associated diseases.Sodium urate crystals can cause foot, joint, soft tissue inflammation and pain.Can be seen by the result of the test of table 1-3
Going out, the Receptaculum Helianthi extract of the present invention can substantially alleviate pain and the swollen pain that chemical substance produces, and shows that having analgesia detumescence makees
With.It addition, the Receptaculum Helianthi extract of the present invention can also significantly inhibit xanthine oxidase activity, reduce the generation of uric acid, hence it is evident that
Reduce blood urea nitrogen, improve renal function.
Claims (10)
1. a Receptaculum Helianthi extract, it is characterised in that comprise total flavones, small-molecular peptides and alkaloid.
2. Receptaculum Helianthi extract as claimed in claim 1, it is characterised in that comprise total flavones 10-20%, small-molecular peptides 1-3%,
Alkaloid 10-30%；Preferably, Receptaculum Helianthi extract comprises total flavones 16-20%, small-molecular peptides 2.4-3%, alkaloid 18-30%.
3. Receptaculum Helianthi extract as claimed in claim 1 or 2, it is characterised in that be prepared into by the method comprised the following steps
To: weighing fresh or freezing and remove the Receptaculum Helianthi of seed, be ground into 80-150 mesh fine powder, the 15-30% ethanol adding 5-10 mass times is molten
Liquid, is placed in flash extracter and carries out broken extraction, and extraction time is 100-300s, and extraction voltage is 100-200V, then profit
Concentrate by suspended crystallization method freezing, concentrated solution adds the compound protease enzymolysis 3-5h of 0.003-0.005 mass times, and
Using doughnut membrane ultrafiltration, filtrate freezing and crystallizing concentrates, and adds appropriate excipient, is spray-dried and get final product.
4. Receptaculum Helianthi extract as claimed in claim 3, it is characterised in that dense for extracting the ethanol solution of Receptaculum Helianthi fine powder
Degree is 18-20%, and freezing temperature is-28 DEG C--40 DEG C.
5. Receptaculum Helianthi extract as claimed in claim 3, it is characterised in that described compound protease is pepsin and pancreas
Protease is in mass ratio for 1:(1.5-3.0) mixture that mixes；Described excipient selected from such as glucose, galactose and/or
Microcrystalline Cellulose.
6. a pharmaceutical composition, it is characterised in that comprise the Receptaculum Helianthi extract as described in one of claim 1-5 with optional
Pharmaceutically acceptable carrier.
7. pharmaceutical composition as claimed in claim 6, it is characterised in that for tablet, capsule, drop pill, granule, powder,
Micropill, solution, syrup, Emulsion or injection.
8. the preparation method of the Receptaculum Helianthi extract as described in one of claim 1-5, it is characterised in that comprise the following steps: claim
Take fresh or freezing and remove the Receptaculum Helianthi of seed, be ground into 80-150 mesh fine powder, add the 15-30% ethanol solution of 5-10 mass times, be placed in
Carrying out broken extraction in flash extracter, extraction time is 100-300s, and extraction voltage is 100-200V, then utilizes the knot that suspends
Crystallization freezing concentrates, and adds the compound protease enzymolysis 3-5h of 0.003-0.005 mass times in concentrated solution, and fine by hollow
Dimension membrane ultrafiltration, filtrate freezing and crystallizing concentrates, adds appropriate excipient, be spray-dried and get final product.
9. the preparation method of Receptaculum Helianthi extract as claimed in claim 8, it is characterised in that ethanol solution concentration is 18-
20%, freezing temperature is-28 DEG C--40 DEG C；Compound protease is pepsin and trypsin is 1 in mass ratio:
(1.5-3.0) mixture mixed；Described excipient is selected from such as glucose, galactose and/or microcrystalline Cellulose.
10. the Receptaculum Helianthi extract as described in one of claim 1-5 or pharmaceutical composition as claimed in claims 6 or 7 exist
Purposes in the medicine of preparation prevention and treatment gout.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610294538.7A CN105878322B (en) | 2016-05-06 | 2016-05-06 | It is a kind of to crystallize sunflower disk extract prepared by enzymatic isolation method and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610294538.7A CN105878322B (en) | 2016-05-06 | 2016-05-06 | It is a kind of to crystallize sunflower disk extract prepared by enzymatic isolation method and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105878322A true CN105878322A (en) | 2016-08-24 |
| CN105878322B CN105878322B (en) | 2017-10-27 |
Family
ID=56703251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610294538.7A Active CN105878322B (en) | 2016-05-06 | 2016-05-06 | It is a kind of to crystallize sunflower disk extract prepared by enzymatic isolation method and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105878322B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106636266A (en) * | 2016-10-12 | 2017-05-10 | 马业忠 | Uric acid-reducing ceramic membrane ultrafiltration technique for small-molecule active peptide of sunflower discs |
| CN107753801A (en) * | 2017-12-06 | 2018-03-06 | 周勇 | Anti-trioxypurine, drop purine treat pharmaceutical composition of gout and preparation method thereof |
| CN108354956A (en) * | 2018-03-08 | 2018-08-03 | 吉林大学 | Sunflower disk powder and its active ingredient are preparing the application in repairing wounded hepatocytes drug |
| CN110327434A (en) * | 2019-08-14 | 2019-10-15 | 吉林省特医食品生物科技有限公司 | A kind of Chinese medicine composition that treating gout, compound Chinese medicinal preparation and preparation method thereof |
| CN110478470A (en) * | 2019-08-28 | 2019-11-22 | 长春中医药大学 | A kind of anti-gout composition of the small-molecular peptides containing sunflower disk and preparation method thereof |
| CN110915980A (en) * | 2019-11-28 | 2020-03-27 | 湖北瑞邦生物科技有限公司 | Sunflower disc peptide powder, and preparation method and application thereof |
| CN111602813A (en) * | 2020-05-27 | 2020-09-01 | 华熙生物科技股份有限公司 | Preparation method of sunflower disc fermentation stock solution for health food and product thereof |
| CN113940375A (en) * | 2021-09-17 | 2022-01-18 | 中国海洋大学 | Processing method for improving prawn quality |
| CN116570640A (en) * | 2023-07-12 | 2023-08-11 | 清枫链食苏打饮品(吉林)有限公司 | Application of sunflower disc alkaloid and derivative in uric acid-reducing and tophus-dissolving product |
| CN116808172A (en) * | 2023-01-07 | 2023-09-29 | 王晓娟 | Sunflower disc liposome and application thereof in preparation of products for reducing uric acid and dissolving tophus |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104087639A (en) * | 2014-07-08 | 2014-10-08 | 吴庆林 | Method for extracting micromolecular active substances from sunflower calathide |
| CN105125610A (en) * | 2015-09-16 | 2015-12-09 | 吉林大学 | Application of sunflower disc hydrolysis compound powder in preparing of medicine for curing or relieving high uric acid gout |
-
2016
- 2016-05-06 CN CN201610294538.7A patent/CN105878322B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104087639A (en) * | 2014-07-08 | 2014-10-08 | 吴庆林 | Method for extracting micromolecular active substances from sunflower calathide |
| CN105125610A (en) * | 2015-09-16 | 2015-12-09 | 吉林大学 | Application of sunflower disc hydrolysis compound powder in preparing of medicine for curing or relieving high uric acid gout |
Non-Patent Citations (1)
| Title |
|---|
| 吉林省民营企业和中小企业协会: "《http://gxt.jl.gov.cn/myqyxh/qydt/20151224_2132829.html》", 24 December 2015 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106636266A (en) * | 2016-10-12 | 2017-05-10 | 马业忠 | Uric acid-reducing ceramic membrane ultrafiltration technique for small-molecule active peptide of sunflower discs |
| CN107753801A (en) * | 2017-12-06 | 2018-03-06 | 周勇 | Anti-trioxypurine, drop purine treat pharmaceutical composition of gout and preparation method thereof |
| CN108354956A (en) * | 2018-03-08 | 2018-08-03 | 吉林大学 | Sunflower disk powder and its active ingredient are preparing the application in repairing wounded hepatocytes drug |
| CN110327434A (en) * | 2019-08-14 | 2019-10-15 | 吉林省特医食品生物科技有限公司 | A kind of Chinese medicine composition that treating gout, compound Chinese medicinal preparation and preparation method thereof |
| CN110478470A (en) * | 2019-08-28 | 2019-11-22 | 长春中医药大学 | A kind of anti-gout composition of the small-molecular peptides containing sunflower disk and preparation method thereof |
| CN110915980B (en) * | 2019-11-28 | 2023-03-14 | 湖北瑞邦生物科技有限公司 | Sunflower head peptide powder, and preparation method and application thereof |
| CN110915980A (en) * | 2019-11-28 | 2020-03-27 | 湖北瑞邦生物科技有限公司 | Sunflower disc peptide powder, and preparation method and application thereof |
| CN111602813A (en) * | 2020-05-27 | 2020-09-01 | 华熙生物科技股份有限公司 | Preparation method of sunflower disc fermentation stock solution for health food and product thereof |
| CN111602813B (en) * | 2020-05-27 | 2022-11-15 | 华熙生物科技股份有限公司 | Preparation method of sunflower disc fermentation stock solution for health food and product thereof |
| CN113940375A (en) * | 2021-09-17 | 2022-01-18 | 中国海洋大学 | Processing method for improving prawn quality |
| CN113940375B (en) * | 2021-09-17 | 2023-05-26 | 中国海洋大学 | Processing method for improving quality of prawns |
| CN116808172A (en) * | 2023-01-07 | 2023-09-29 | 王晓娟 | Sunflower disc liposome and application thereof in preparation of products for reducing uric acid and dissolving tophus |
| CN116808172B (en) * | 2023-01-07 | 2024-02-13 | 龚曙初 | Sunflower disc peptide, composite liposome and application thereof in preparation of products for reducing uric acid and dissolving tophus |
| CN116570640A (en) * | 2023-07-12 | 2023-08-11 | 清枫链食苏打饮品(吉林)有限公司 | Application of sunflower disc alkaloid and derivative in uric acid-reducing and tophus-dissolving product |
| CN116570640B (en) * | 2023-07-12 | 2023-09-05 | 清枫链食苏打饮品(吉林)有限公司 | Application of sunflower disc alkaloid and derivative in uric acid-reducing and tophus-dissolving product |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105878322B (en) | 2017-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105878322A (en) | Sunflower head extract prepared by crystallization enzymolysis method and preparation method of sunflower head extract | |
| US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
| CN100415280C (en) | A Chinese traditional medicinal preparation for treatment of urticaria | |
| CN105920067A (en) | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN102258680B (en) | Chinese medicinal composition for reliving physical fatigue and preparation method and use thereof | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN109942491B (en) | Anti-inflammatory and analgesic C in monkshood20Diterpene alkaloid and application thereof | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN102614243B (en) | Method for extracting common macrocarpium fruit total glycoside and application of common macrocarpium fruit total glycoside to preparation of hypoxia tolerant medicines | |
| CN105412898A (en) | Application of traditional Chinese medicine composition in preparing acute nephritis | |
| CN103768570B (en) | A kind of Chinese medicine composition for the treatment of acute cholecystitis and preparation method thereof | |
| CN107625796B (en) | Pharmaceutical composition containing radix angelicae and application thereof | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| KR20160086457A (en) | Composition comprising alcohol extract of GamiBangkeehwangkeetang for preventing and treating a rheumatoid arthritis | |
| CN103251667A (en) | Application of general inula helenium sesquiterpene lactone in preparation of medicine for treating rheumatoid arthritis | |
| CN110742983B (en) | Traditional Chinese medicine preparation for treating acute gout attack and preparation method thereof | |
| CN102028918B (en) | Application of Tibetan medicinal composition to preparation of medicament for treating cerebral circulation insufficiency | |
| CN110585267A (en) | Pharmaceutical composition with thrombin activity inhibition function and application thereof | |
| CN102475780B (en) | Preparation method for traditional Chinese drug composition for treating primary hypertension | |
| CN106177480A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Herba Dendrobii | |
| CN114748440A (en) | Astragalus membranaceus and astragalus membranaceus capsule composition for increasing leucocyte and its preparation method and use | |
| CN102670785A (en) | Preparation method of conventional Chinese medicine composition for treating primary hypertension | |
| CN103623351B (en) | Stroke rehabilitation revival pill and preparation method thereof | |
| CN102526192B (en) | Traditional Chinese medicine combination for clearing heat and calming livers and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Sunflower head extract prepared by crystallization enzymolysis method and preparation method of sunflower head extract Effective date of registration: 20180904 Granted publication date: 20171027 Pledgee: Shanghai Pudong Development Bank Limited by Share Ltd. Changchun branch Pledgor: TAONAN JINTA BIOTECHNOLOGY Co.,Ltd. Registration number: 2018220000032 |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20191028 Granted publication date: 20171027 |
|
| PP01 | Preservation of patent right | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20221028 Granted publication date: 20171027 |
|
| PD01 | Discharge of preservation of patent | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20221104 Granted publication date: 20171027 |
|
| PP01 | Preservation of patent right |